Common variants, en masse, may add up to strong autism risk

Individually, common genetic variants confer little risk for autism. But taken together, they may contribute significantly, predicts a statistical analysis published 15 October in Molecular Autism¹.

Common variants are typically defined as those found in more than five percent of the population, and rare variants as those found in less than one percent.

Researchers predict that cumulatively, common variants contribute as much as 40 percent of autism risk in families with one child who has the disorder, and 60 percent in families with more than one affected member.

The report is the result of a sophisticated statistical analysis based on data from about 2,000 families. It is the latest contribution to a long-running debate over whether relatively common diseases such as autism stem from rare mutations that individually have large effects, or from a combination of many common variants that each exert small effects.

The new finding falls squarely in the middle.

“[Autism risk] is neither only rare nor only common,” says lead investigator Bernie Devlin, professor of psychiatry at the University of Pittsburgh. “We provide sound evidence that common variants en masse exert a large effect on risk.”

Others are skeptical about the magnitude of risk the model predicts, however.

“Common variants are clearly important, but whether they account for half of the risk, this paper doesn’t prove or disprove that,” says Hakon Hakonarson, associate professor of pediatrics at the University of Pennsylvania School of Medicine, who has published research on both common and rare variants. “We still need much more data to convincingly show that this is the case.”

Still, says Hakonarson, the findings do suggest that common variants are worth studying. “There are so many voices in the field telling us to ignore common variants,” he says. “But this gives us more balance.”

Swinging pendulum:

The debate over the relative contributions of common and rare variants has been driven in large part by the technologies available. The advent of gene microarrays nearly ten years ago enabled scientists to quickly and cheaply search the genome for common genetic variants, known as single nucleotide polymorphisms, or SNPs.

That in turn triggered a flood of genome-wide association studies (GWAS), which are designed to detect common variants that occur more frequently in people with a certain disease than in others. But GWAS approaches to autism have been somewhat disappointing.

For example, an analysis published in August of more than 2,700 families who are part of the Autism Genome Project (AGP) found no SNPs that are significantly linked to autism or to symptoms associated with the disorder².

In the new study, rather than look for individual SNPs, Devlin and his collaborators used statistical modeling to determine whether common variants overall contribute to risk. They focused their analysis on GWAS data from two large projects — the AGP, which includes data from multiplex families, in which one or more children are affected, and the Simons Simplex Collection (SSC), a database of families that have a single child with autism and unaffected parents and siblings. The SSC is sponsored by the Simons Foundation, SFARI.org’s parent organization.

Altogether, the researchers compared data frommore than 2,000families with a history of autism and 1,600 control individuals.

In simplified terms, the researchers used the SNP data to calculate the distant relatedness between everyone in the sample, generating a massive pedigree.

“People who are more closely related tend to have autism and those who are more distantly related do not, consistent with the idea that common variation is driving some heritability of disease,” says Andrew Paterson, Canada Research Chair in Genetics of Complex Diseases at the University of Toronto, who was not involved in the study.

The fact that both datasets, which include different types of families, arrive at similar results supports the idea that common variants contribute significantly to autism, says Hakonarson. “But nothing in the paper says this is clearly the case.”

Additive effect:

Rather than debate the relative contributions of common and rare variants, the researchers say it’s time to look at how the two types of variants work together.

“As we move forward in sorting this out, it will begin to give us an opportunity to understand the relationship between common variants and rare variants,” says Matthew State, co-director of the Yale Program on Neurogenetics and one of the researchers on the study.

“We don’t know yet how much overlap there will be among different types of risk,” he says. “Overall, this understanding is likely to open important doors to get a handle on things like genetic modifiers.”

Genetic modifiers can influence the outcome of a mutation. For example, rare variants can cause highly variable symptoms, suggesting additional genetic or environmental factors at play. Devlin says common variants may modify the effect of the rare risk variants.

Some companies have already begun to market diagnostic tests that predict an individual’s risk of autism based on a set of SNPs. But Devlin says his findings have little clinical relevance. “[Individual] common variants are going to be very difficult to find,” he says.

There is also little agreement among the experts over the best way to move forward. 

Hakonarson favors sequencing DNA from large numbers of individuals with autism — 20,000 to 30,000 — which he says is likely to give a much more accurate estimate of the percentage of risk that can be attributed to common variants. Paterson says larger GWAS are needed, perhaps on the order of tens of thousands.

Devlin suggests better analysis of existing SNP data. “There may be smart ways of looking at data where you might be able to eke out some of the common variants without huge sample sizes,” he says.

References:

1: Klei L. et al. Mol. Autism Epub ahead of print (2012) Abstract

2: Anney R. et al. Hum. Mol. Genet. Epub ahead of print (2012) PubMed